Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Syndax Pharmaceuticals
Biotech
Syndax stock slips after AML drug hits midstage trial goal
The treatment’s overall response rate was 47% in the phase 2 portion of the trial, down from 63% in the phase 1 part.
Darren Incorvaia
Nov 12, 2024 2:00pm
A SMRT new target for male contraceptives works in mice
Feb 22, 2024 3:35pm
Syndax slips as pivotal cancer trial stopped early for efficacy
Oct 2, 2023 9:40am
Ex-J&J research chief lands at FogPharma—Chutes & Ladders
Mar 31, 2023 9:30am
Roche taps new North American diagnostics chief—Chutes & Ladders
Dec 9, 2022 9:30am
Syndax, Incyte pen chronic graft-versus-host disease collab
Sep 27, 2021 7:25am
